A 6-month trial to see if nicotine had an effect on people with mild cognitive impairment (MCI) was conducted used Nicotrol patches.
The researchers conducting the study did not find nicotine to be addictive in people who had never smoked, nor even in the small number of non-smoking former smokers who were included in the trial.
The lead researcher, Dr. Paul Newhouse, later said that nicotine:
“seems very safe even in nonsmokers. In our studies we find it actually reduces blood pressure chronically. And there were no addiction or withdrawal problems, and nobody started smoking cigarettes. The risk of addiction to nicotine alone is virtually nil.”
Dr. Newhouse also stated:
“nicotine by itself isn’t very addictive at all... [it] seems to require assistance from other substances found in tobacco to get people hooked.”
_________
Published in the Journal Neurology 2012 Jan 10; 78(2): 91–101.
(The official Journal of the American Academy of Neurology)
Nicotine treatment of mild cognitive impairment
A 6-month double-blind pilot clinical trial
P. Newhouse et al.
From the Abstract: Methods
Nonsmoking subjects with amnestic MCI [mild cognitive impairment] were randomized to transdermal nicotine (15 mg per day or placebo) for 6 months.
________
From the Full Study: Methods - Medication
Transdermal nicotine was begun utilizing a 5 mg Nicotrol® patch (Pharmacia/Pfizer) transdermal delivery system, in sizes of 10, 20, and 30 cm2 each containing 0.83 mg/cm2 of nicotine, releasing 5 mg, 10 mg, and 15 mg, respectively, over 16 hours or matching placebo. Treatment (active or placebo) was titrated to 15 mg by day 21. Subjects were contacted by phone during the first week and returned after 7 and 28 days to monitor side effects and medication compliance.
________
From the Full Study: Discussion
There was no withdrawal syndrome and no subjects continued to use nicotine products. Thus, in this nonsmoking population, there was no evidence for abuse liability of transdermal nicotine. Only nonsmokers were utilized for this study to simplify dose-ranging. As former smoking status was not a focus of this study and the number of former smokers was small, an analysis of prior smoking status and efficacy was not performed. Whether these findings of cognitive enhancement would apply to individuals with substantial histories of tobacco use or active smoking will require further study and potentially different dose ranges.